Physical Review a最新文献_第2页

Using biomarkers to allocate patients in a response-adaptive clinical trial. 使用生物标志物在反应适应性临床试验中分配患者。

IF 2.6 2区物理与天体物理

Physical Review a Pub Date : 2023-12-02 Epub Date: 2021-11-25 DOI: 10.1080/03610918.2021.2004420

H Jackson, S Bowen, T Jaki

引用次数: 0

Mitochondrial DNA Sensing Pathogen Recognition Receptors in Systemic Sclerosis Associated Interstitial Lung Disease: A Review. 系统性硬化症相关间质性肺病中的线粒体 DNA 感知病原体识别受体：综述。

2区物理与天体物理

Physical Review a Pub Date : 2023-12-01 Epub Date: 2023-08-08 DOI: 10.1007/s40674-023-00211-1

Alexander Ghincea, Samuel Woo, Sheeline Yu, Taylor Pivarnik, Vitoria Fiorini, Erica L Herzog, Changwan Ryu

{"title":"Mitochondrial DNA Sensing Pathogen Recognition Receptors in Systemic Sclerosis Associated Interstitial Lung Disease: A Review.","authors":"Alexander Ghincea, Samuel Woo, Sheeline Yu, Taylor Pivarnik, Vitoria Fiorini, Erica L Herzog, Changwan Ryu","doi":"10.1007/s40674-023-00211-1","DOIUrl":"10.1007/s40674-023-00211-1","url":null,"abstract":"Purpose of the review: Systemic sclerosis (SSc) is a condition of dermal and visceral scar formation characterized by immune dysregulation and inflammatory fibrosis. Approximately 90% of SSc patients develop interstitial lung disease (ILD), and it is the leading cause of morbidity and mortality. Further understanding of immune-mediated fibroproliferative mechanisms has the potential to catalyze novel treatment approaches in this difficult to treat disease.Recent findings: Recent advances have demonstrated the critical role of aberrant innate immune activation mediated by mitochondrial DNA (mtDNA) through interactions with toll-like receptor 9 (TLR9) and cytosolic cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS).Summary: In this review, we will discuss how the nature of the mtDNA, whether oxidized or mutated, and its mechanism of release, either intracellularly or extracellularly, can amplify fibrogenesis by activating TLR9 and cGAS, and the novel insights gained by interrogating these signaling pathways. Because the scope of this review is intended to generate hypotheses for future research, we conclude our discussion with several important unanswered questions.","PeriodicalId":48702,"journal":{"name":"Physical Review a","volume":"70 1","pages":"204-220"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10791121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84228806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"物理与天体物理","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When Is the Optimum Radiological Response to Proton Beam Therapy in Uveal Melanoma? 质子束疗法对葡萄膜黑色素瘤的最佳放射反应是什么时候？

IF 2.6 2区物理与天体物理

Physical Review a Pub Date : 2023-12-01 Epub Date: 2023-08-02 DOI: 10.1159/000533308

Matthew Gillam, Glenn Ace Fenech, Oliver Chadwick, Jonathan Nairn, Vikas Chadha, Julie Connolly, Oliver Cram, Wilma Kincaid, Paul Cauchi

{"title":"When Is the Optimum Radiological Response to Proton Beam Therapy in Uveal Melanoma?","authors":"Matthew Gillam, Glenn Ace Fenech, Oliver Chadwick, Jonathan Nairn, Vikas Chadha, Julie Connolly, Oliver Cram, Wilma Kincaid, Paul Cauchi","doi":"10.1159/000533308","DOIUrl":"10.1159/000533308","url":null,"abstract":"Introduction: Proton beam therapy (PBT) is an effective treatment option for uveal melanomas. Following treatment, it may take many months for the tumour to respond and it may initially enlarge. We reviewed our PBT patients to determine when they showed a radiological response to treatment.Methods: Patients undergoing PBT for ciliary body or choroidal melanomas between 2008 and 2018 were included. Data were collected on patient demographics, treatments before and after PBT and survival. All ultrasound investigations prior and since PBT were reviewed and tumour volume calculated using a validated formula for a half-ellipsoid shape.Results: 193 patients were analysed, 169 with choroidal and 24 with ciliary body melanomas. 31.6% patients had other treatment prior to PBT. At a mean of 8 months post-PBT, 64.7% of patients had a reduced tumour volume with 20.2% having larger tumours. At a mean of 15 months post-treatment, these figures were 67.8% and 10.3%. 18.1% of patients had an enucleation during the study period. The earliest responses were seen at 2 months, the latest at 32 months post-treatment. 5-year melanoma-specific survival was 82.3%.Conclusions: In our study, by 6 months post-PBT, a majority of patients show a reduction in tumour volume. Of those that do not, many respond in the next 6 months and a response may be seen up to 32 months after treatment. Patients may need to be monitored for up to 32 months to see a final response to PBT treatment.","PeriodicalId":48702,"journal":{"name":"Physical Review a","volume":"67 1","pages":"130-137"},"PeriodicalIF":2.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84057557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"物理与天体物理","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Algebraic relations from finite-nuclear-mass effects to test atomic transition rates 有限核质量效应与原子跃迁率测试的代数关系

IF 2.9 2区物理与天体物理

Physical Review a Pub Date : 2023-09-08 DOI: 10.1103/physreva.108.032807

A. Bondy, G. W. F. Drake